Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Pruritus
Interventions: Dupilumab 300Mg Solution for Injection; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
Interventions: Etanercept, Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Duncansville, Pennsylvania • Dallas, Texas

Conditions: Breast Cancer
Interventions: Radiolucent cushion; Device
Lead sponsor: University of Kansas; Other
Eligibility: 40 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Patient Positioning, Monitoring, Physiologic, Pressure Ulcer
Interventions: Zephyr BioPatch; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Isosulfan blue, Axillary Lymph Node Dissection, Surgery, Sentinel Lymph Node Biopsy, Thoracoscopic Surgery, Technetium Tc 99m Sulfur Colloid; Drug · Procedure · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Calcinosis Cutis
Interventions: Sodium Thiosulfate, Saline Solution; Drug · Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Breast Cancer, Adherence, Medication
Interventions: STRIDE, Medication Monitoring Control; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Months and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Squamous Cell Carcinoma
Interventions: Afatinib 40 MG; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Actinic Keratoses
Interventions: Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India; Drug
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more

Conditions: Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions: therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction; Biological · Procedure · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
Interventions: KB707, Opdualag, KEYTRUDA ®( Pembrolizumab); Biological · Drug
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Rancho Santa Margarita, California • Weston, Florida + 12 more

Conditions: Polymyositis, Dermatomyositis
Interventions: BAF312, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rosacea
Interventions: Imipramine, Amitriptyline, Vehicle; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
Interventions: PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine); Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: Dabrafenib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions: Nivolumab, Nivolumab + Relatlimab, Ipilimumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: glp1 Agonist, Gene Expression, Skin Laxity
Interventions: ellacor; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dublin, California

Conditions: Breast Cancer
Interventions: Fulvestrant, MLN9708; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Breast Cancer, Lymphedema
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Saint Louis Park, Minnesota

Conditions: Venous Leg Ulcer
Interventions: Cirvo™ Therapy; Device
Lead sponsor: Radial Medical, Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Allergy Pollen
Interventions: Spiriplex Allergenex Microassay; Diagnostic Test
Lead sponsor: United Allergy Services; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Laxity; Skin
Interventions: On GLP1 plus HRT, On GLP1 Only; Drug
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hidradenitis Suppurativa (HS)
Interventions: ORKA-002, Placebo; Drug · Other
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 17 more

Conditions: Hidradenitis Suppurativa
Interventions: Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment; Drug · Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Effects of Denosumab on the Pharmacokinetics of Etanercept

Use of a Radiolucent Pad to Reduce Mammography Among African Americans

An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Saline for Dystrophic and Idiopathic Calcinosis Cutis

Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

Phase I Study of the Combination of MLN9708 and Fulvestrant

Predictors of Lymphedema Following Breast Cancer Surgery

Evaluation of Cirvo™ Mobile Compression Device for Treatment of Venous Leg Ulcers

Microassay and Allergy Skin Prick Test Correlation Study

Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa